Table 1 Cross-sample comparisons in demographics and clinical profiles for two samples of individuals with schizophrenia.
Measure | Drug-naïve FES sample (N = 59) | Antipsychotic-treated sample (N = 115) | t/χ2 | p-value |
|---|---|---|---|---|
Age (M [SD], years) | 28.46 (9.24) | 45.95 (7.10) | −12.73 | <0.001 |
Sex (Female, N/N%) | 31 (52.5%) | 41 (35.7%) | 4.59 | 0.032 |
Education level (M [SD], years) | 11.05 (3.40) | 10.15 (3.10) | 1.71 | 0.090 |
Illness duration (M [SD], months) | 20.07 (37.44) | 229.26 (106.53) | −18.84 | <0.001 |
Length of current hospitalization (M [SD], days) | NA | 704.02 (1020.71) | NA | NA |
Total length of hospitalization (M [SD], days) | NA | 1433.49 (1016.71) | NA | NA |
Number of lifetime hospitalization (M [SD]) | NA | 6.52 (6.24) | NA | NA |
CPZ equivalent (M [SD], mg/day) | NA | 559.20 (312.33) | NA | NA |
Antipsychotic type (n/%) | NA | NA | NA | NA |
Typical antipsychotics | NA | 11 (9.6%) | NA | NA |
Atypical antipsychotics | NA | 79 (68.7%) | NA | NA |
Mixed types of antipsychotics | NA | 20 (17.4%) | NA | NA |
Not available | NA | 5 (4.3%) | NA | NA |
PANSS (M [SD]) | NA | NA | NA | NA |
Positive score | 24.93 (3.61) | 10.61 (4.74) | 22.06 | <0.001 |
Negative score | 23.22 (4.71) | 16.04 (5.45) | 8.97 | <0.001 |
General psychopathological score | 48.32 (6.68) | 25.79 (6.07) | 21.61 | <0.001 |
Total score | 96.47 (11.39) | 52.44 (13.88) | 22.25 | <0.001 |
GAF (M [SD]) | 50.25 (15.24) | 59.53 (14.85) | −3.82 | <0.001 |
